Accelerating Medicine Partnership in Alzheimer’s Disease
AMP-AD is a public private partnership designed to use systems biology to identify novel targets for AD treatment
The Accelerating Medicines Partnership – Alzheimer’s Disease Target Discovery and Preclinical Validation project is aimed at reducing the time between discovery of potential drug targets and the development of new drugs to prevent or treat Alzheimer’s disease. This project is a component of the broader AMP-AD program, a National Institutes on Aging-led precompetitive, public-private partnership that is managed by the Foundation for the National Institutes of Health. The Target Discovery and Preclinical Validation Project brings together six multi-institutional, cross-disciplinary academic teams, four industry partners, and four non-profit organizations. The academic teams, supported by NIA grants, are applying cutting-edge systems and network biology approaches to integrate multidimensional human molecular data (genomic, epigenomic, RNA, proteomic) from more than 2,000 human brains at all stages of Alzheimer’s disease with clinical and pathological data.
The project is focused on the following goals:
- Discover novel therapeutic targets for Alzheimer’s disease;
- Gain a systems-level understanding of how these novel targets operate within gene, protein, and metabolic networks;
- Evaluate the druggability of these novel targets in multiple model organisms.
More Scientific Coordination Projects
Multi-Consortia Coordinating (MC2) Center
Sage Bionetworks leads the Multi-Consortia Coordinating (MC2) Center for six research consortia from the NIH/NCI Division of Cancer Biology. The MC2 Center aims to catalyze...
Learn MoreThe Gray Foundation
The Gray Foundation "Team Science" philanthropic initiative funds a network of researchers to study new approaches for the early detection, diagnosis, and therapy of BRCA-related...
Learn MoreThe First 1000 Days 1kD
The 1kD program is an international effort to better understand executive development in toddlers up to 1000 days old.
Learn More